Engineered human iPSC-derived dendritic cells dressed with tumor MHC complexes as a cancer vaccine.

PD-L1/2-null TumorDressed dendritic cells significantly enhance T cell activation and cytotoxicity against primary hematologic and solid tumors in vitro and in vivo.

• Why it matters: Effective cancer vaccines require high-quality, diverse antigen presentation, but current autologous dendritic cell approaches face limitations in quantity and antigen diversity, hindering their therapeutic potential.
• What they did: Researchers differentiated universal MHC-deficient human-induced pluripotent stem cells into migratory dendritic cells, then "dressed" them with tumor MHC-antigen complexes, and tested their ability to activate T cells.
• The result: PD-L1/2 deletion in TumorDressed DCs markedly improved their capacity to prime anti-tumor T cell responses, supporting their development as a universal, scalable off-the-shelf cancer vaccine platform.